Bellevue Group Ag Arcutis Biotherapeutics, Inc. Transaction History
Bellevue Group Ag
- $5.93 Billion
- Q3 2024
A detailed history of Bellevue Group Ag transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 39,500 shares of ARQT stock, worth $500,860. This represents 0.01% of its overall portfolio holdings.
Number of Shares
39,500
Previous 17,500
125.71%
Holding current value
$500,860
Previous $162,000
126.54%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$148 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$139 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$136 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$111 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$109 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $763M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...